text_1: GSK hands back failed muscular dystrophy drug to Prosensa.
text_2: GlaxoSmithKline has handed back rights to an experimental drug for Duchenne muscular dystrophy to U.S.-listed Dutch biotech firm Prosensa after it failed last year in a critical clinical trial.